Fengrong Zuo received her Molecular & Cellular Biology Ph.D. degree from McArdle Cancer Institute at University of Wisconsin Madison and did her post-doctoral training in an immunology laboratory at Stanford University. Fengrong is a Principal Scientist currently leading the Cell-based and Serology group in the Translational Medicine Department at MedImmune/Astrazeneca. She directs the team on development and validation of important bioassays fit for use as biomarkers in epidemiology and clinical studies in support of MedImmuneâ€™s infectious disease,monoclonal antibody, and vaccine drug candidate development, starting from late stage research to commercialization. Before joining MedImmune, Fengrong worked in the Biological Technology Department at Genentech for 3+ years as the group leader of potency assay validation, which was responsible for assay development and validation for QC lot release and stability studies of Mab drug candidates used in the treatment of oncology and autoimmune diseases. Prior to Genentech, she worked at Roche-Palo Alto for 9+ years for target identification, validation, and small molecule drug development by utilizing her expertise in cellular pharmacology and bioassay development for drug screening. Fengrong is considered as SME in bioassay and GXP compliance areas because of her 15+ years of research, CMC, and clinical bioassay development, as well as, validation and agency filing experiences.